Disc Medicine Files 8-K, Details Corporate History

TL;DR

Disc Medicine (formerly Gemini/FS Dev) filed an 8-K on 10/25, updating corporate info.

AI Summary

Disc Medicine, Inc. filed an 8-K on October 25, 2024, reporting on other events and financial statements. The company was formerly known as Gemini Therapeutics, Inc. and FS Development Corp. before name changes on February 9, 2021, and July 2, 2020, respectively. The filing details its principal executive offices located at 321 Arsenal Street, Suite 101, Watertown, Massachusetts.

Why It Matters

This filing provides a historical record of corporate name changes and current operational details for Disc Medicine, Inc., which is important for understanding the company's evolution and current structure.

Risk Assessment

Risk Level: low — The filing is primarily administrative and historical, with no immediate financial or operational risks disclosed.

Key Players & Entities

• Disc Medicine, Inc. (company) — Registrant
• Gemini Therapeutics, Inc. (company) — Former Company Name
• FS Development Corp. (company) — Former Company Name
• 20210209 (date) — Date of Gemini Therapeutics, Inc. name change
• 20200702 (date) — Date of FS Development Corp. name change
• 321 Arsenal Street, Suite 101 (location) — Principal Executive Offices
• Watertown, Massachusetts (location) — Principal Executive Offices Location

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share IRON The Nasdaq Global Ma

Filing Documents

• iron-20241025.htm (8-K) — 61KB
• iron-ex99_1.htm (EX-99.1) — 25KB
• img57926557_0.jpg (GRAPHIC) — 19KB
• img57926557_1.jpg (GRAPHIC) — 19KB
• 0000950170-24-117318.txt ( ) — 261KB
• iron-20241025.xsd (EX-101.SCH) — 25KB
• iron-20241025_htm.xml (XML) — 5KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 25, 2024, Disc Medicine, Inc. (the "Company") issued a press release announcing the Company's data presented at the 2024 American Society of Nephrology (ASN) Kidney Week. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such filing. The Company undertakes no obligation to update, supplement or amend the material attached hereto as Exhibit 99.1.

01 Other Events

Item 8.01 Other Events. On October 25, 2024, the Company reported positive additional data from its ongoing Phase 1b clinical trial of DISC-0974 in patients with non-dialysis-dependent chronic kidney disease ("NDD-CKD") and anemia, including results from the 40 mg and 60 mg single ascending dose ("SAD") cohorts. In the SAD portion of this trial, participants with Stage 2-5 NDD CKD were given a single dose of placebo (n=7) or DISC-0974 subcutaneously (SC) at 28 mg (n=9), 40 mg (n=6), or 60 mg (n=6). Dose escalation is ongoing in the SAD. This interim data set demonstrated: Substantial, durable, dose-dependent reduction in hepcidin from baseline compared to placebo across dose levels, with median reduction greater than 75% from baseline at highest dose level Meaningful and sustained increase in transferrin saturation from baseline compared to placebo across dose levels, with median increase up to 3x from baseline at highest dose level Early and sustained increase in mean reticulocyte hemoglobin from baseline across all dose groups through Day 22 and beyond Maximal mean values through Day 22 of +1.14 pg at 28 mg, +1.49 pg at 40 mg, and +1.53 pg at 60 mg, compared with +0.21 pg on placebo Increase in mean hemoglobin from baseline across dose groups over the study period Change greater than placebo: +0.35 g/dL at 28 mg, +0.54 g/dL at 40 mg, and +0.55 g/dL at 60 mg Mean maximal increase in hemoglobin of +0.8 g/dL at 40 mg and +0.7 g/dL at 60 mg compared with +0.2 g/dL on placebo Maximal observed individual increase in hemoglobin up to +0.95 g/dL at 28 mg, +1.5 g/dL at 40 mg, and +1.8 g/dL at 60 mg DISC-0974 demonstrated acceptable safety and tolerability at all evaluated dose levels The majority of adverse events were deemed not related to DISC-0974 and all adverse events assessed as treatment-related were Grade 1 or 2 DISC-0974 is an investigational agent and is not approved for therapeutic use in any jurisdiction worldwide.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by Disc Medicine, Inc. on October 25, 2024, furnished herewith 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DISC MEDICINE, INC. Date: October 25, 2024 By: /s/ John Quisel, J.D., Ph.D. Name: Title: John Quisel, J.D., Ph.D. Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR